A deal for Ventyx would help Lilly compete in the promising space. If Ventyx’s experimental pills pan out, they would add to ...

It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...

Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than $1 billion, the Wall Street Journal reported on ...

Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

Ventyx Biosciences makes drugs that help with immunological and inflammatory illnesses. If Lilly buys the company, it will be ...

Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...

Ventyx shares jumped in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the biopharma ...

A report in the Wall Street Journal, citing people familiar with the matter, suggested an announcement of a transaction could ...

Eli Lilly has announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, a biopharmaceutical ...

Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space ...

Detailed price information for Ventyx Biosciences Inc (VTYX-Q) from The Globe and Mail including charting and trades.